Suscribirse

Periurethral Abscess Following Urethral Reconstruction: Clinical Features and Prognosis - 17/03/22

Doi : 10.1016/j.urology.2021.12.020 
Grayden S. Cook, Mehraban Kavoussi, Shervin Badkhshan, Gianpaolo P. Carpinito, Benjamin M. Dropkin, Raj R. Bhanvadia, Gregory A. Joice, Samantha W. Nealon, Sarah C. Sanders, Steven J. Hudak, Allen F. Morey
 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 

Address correspondence to: Allen F. Morey, M.D., Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9110.Department of UrologyUniversity of Texas Southwestern Medical Center5323 Harry Hines Blvd.DallasTX75390-9110

Abstract

Objective

To evaluate the clinical and prognostic details of periurethral abscess (PUA) formation following urethroplasty (UP).

Methods

A retrospective review was performed to identify men who developed PUA after UP between 2007 and 2019 at a single tertiary care referral center. Patient demographics, stricture characteristics, and UP technique were recorded. Outcomes included time to PUA, presenting symptoms, wound cultures, imaging, and ultimate management. Comparative analysis between PUA and non-PUA patients was performed using Fisher's Exact test and Student's t-test.

Results

Among 1499 UP cases, 9 (0.6%) developed PUA. Mean stricture length was 4.6 cm with most located in the bulbar urethra (5/9, 56%), while 4/9 (44%) had undergone prior UP. PUA rates were 7/288 (2.4%) and 2/815 (0.3%) for substitution and anastomotic UP respectively. Voiding cystourethrogram (VCUG) demonstrated extravasation in 67% (4/6) of available UP cases imaged. Subsequent VCUG confirmed leak improvement or resolution in all cases. Wound cultures were frequently polymicrobial (4/6, 67%). Management included antibiotics with (6/9) and without (3/9) incision and drainage (I/D). Urinary drainage was performed in 5 patients using suprapubic tube (3/5) and foley placement (2/5). PUA resolution was observed in all patients while stricture symptom recurrence was observed in 2/9 (22%) patients with mean time to recurrence of 15 months. Overall mean follow-up time was 22 months.

Conclusion

PUA is a rare complication of UP that may be more common in setting of postoperative urine leak. PUA is safely managed with I/D, urethral rest, and antibiotics, with low risk of recurrent stricture formation thereafter.

El texto completo de este artículo está disponible en PDF.

Esquema


 Financial Disclosure: Dr. Allen Morey receives honoraria for being a guest lecturer/meeting participant for Boston Scientific and Coloplast Corp. Dr. Steven Hudak is a paid speaker/consultant for Boston Scientific Corp. No other authors have any disclosures to present.


© 2021  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 161

P. 111-117 - mars 2022 Regresar al número
Artículo precedente Artículo precedente
  • Barriers to Implementation of a Same-Day Discharge Pathway for Holmium Laser Enucleation of the Prostate
  • Jenny Guo, Matthew S. Lee, Mark Assmus, Amy E. Krambeck
| Artículo siguiente Artículo siguiente
  • Robotic Urethral Reconstruction Outcomes in Men With Posterior Urethral Stenosis
  • Elizabeth N. Bearrick, Bridget L. Findlay, Laura A. Maciejko, Kevin J. Hebert, Katherine T. Anderson, Boyd R. Viers

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.